Team Philippe MARIN

Neuroproteomics and signalling of brain disorders

Philippe Marin
DRCE, CNRS

The team is developing a multidisciplinary strategy combining genomics and proteomics approaches with pharmacological, biochemical, cell biology, electrophysiological and behavioral studies to decipher the neuronal mechanisms involved in various neurological and psychiatric disorders (mood disorders, psychoses, autism, Alzheimer’s disease, multiple sclerosis) and identify biomarkers of these pathologies.

Our research aims at characterizing the pathophysiological mechanisms of neurological (Alzheimer’s disease, multiple sclerosis, gliomas) and psychiatric (depression, schizophrenia, autism spectrum disorders) disorders, in order to identify targets for innovative therapies and biomarkers. It cover molecular mechanisms, with a focus on signaling networks associated with various G protein-coupled receptors that are potential targets for the pathologies studied (serotonin, glutamate and chemokine receptors), which we characterize using interactomic or phosphoproteomic screens, cellular mechanisms (intracellular trafficking, secretion and paracrine diffusion of pathological proteins), synaptic mechanisms (transmission and plasticity) and changes in brain connectivity and network activity, in particular alteration of the excitation/inhibition balance. Particular attention is paid to neurodevelopmental mechanisms and environmental factors (microbiota, diet, etc.). The team is also deeply involved in environmental issues and the impact of climate change on mental health.

Within this general framework, the team is developing the following lines of research under the direction of project leaders:
• Interactomics and neuropathologies
• Microbiota, serotonin and neurodegenerative diseases
• Serotonin receptors and psychiatric disorders
• Identification and functional analysis of multiple sclerosis biomarkers
• Homeostasis and Physiological Dysregulation in Alzheimer’s Disease
• Temperature and Circadian control of Alzheimer’s disease pathophysiology
• Protein trafficking and neurodegenerative diseases
• Normal and pathological functions of Tau / Eco-emotions and mental health
• Neuron-Glia communication during developmental and pathological neurodegeneration
• GPCR signaling, compartmentalization and pathophysiological roles

Colocalization of ACKR3 and Connexin 43 (receptor’s partner identified by interactomics) in mouse brain astrocytes. ACKR3 (cyan), Cx43 (pink), GFAP (white). Adapted from Fumagalli et al. Nat. Commun. 2020.

Team leader
Philippe
Marin
DRCE, CNRS
  IGF Sud 215
  04 34 35 92 42
Know more >

Researchers
Carine
Becamel
PU, UM
  IGF Sud 224
  04 34 35 92 15
Know more >

Joel
Bockaert
PU, UM
  IGF Sud 215
  04 34 35 92 42
Know more >

Olivier
Caillard
CRCN, CNRS
  IGF Sud 224
  04 34 35 92 15
Know more >

Geoffrey
Canet
CRCN, CNRS
  IGF Sud 219
  04 34 35 92 23
Know more >

Séverine
Chaumont-Dubel
MCF, UM
  IGF Sud 029
  04 34 35 92 17
Know more >

Sylvie
Claeysen
CRHC, Inserm
  IGF Sud 224
  04 34 35 92 15
Know more >

Philippe
Coubes
PU-PH1, UM
  IGF Sud 224
  04 34 35 92 15
Know more >

Laurent
Givalois
CRCN, CNRS
  IGF Sud 219
  04 34 35 92 23
Know more >

Marie-Laure
Parmentier
DR2, Inserm
  IGF Sud 225
  04 34 35 93 19
Know more >

Éric
Thouvenot
PU-PH1, UM
  IGF Sud 221
  04 34 35 92 13
Know more >

Julien
Villeneuve
CRCN, CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Technicians and engineers
Ana
Boulanger
IR CDI, CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Sonya
Galant
IECN, CNRS
  IGF Sud 221
  04 34 35 92 13
Know more >

Magali
Lançon
TCE, UM
  IGF Sud 204
  04 34 35 92 16
Know more >

Postdoctoral researchers and doctoral students
Léo
Boussamet
Chercheur CDD, CNRS
  IGF Sud 224
  04 34 35 92 15
Know more >

Antoine
Carpentier
Doctorant(e), UM
  IGF Sud 224
  04 34 35 92 15
Know more >

Maëlle
Colladant
Doctorant(e), UM
  IGF Sud 224
  04 34 35 92 15
Know more >

Thomas
Curel
Doctorant(e), Inserm
  IGF Sud 224
  04 34 35 92 15
Know more >

Soufiane
El Khayari
Doctorant(e), UM
  IGF Sud 220
  04 34 35 92 13
Know more >

Charline
Gal
Doctorant(e), CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Eloise
Neel
Doctorant(e), CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Clemence
Quittet
Doctorant(e), UM
  IGF Sud 221
  04 34 35 92 13
Know more >

Manon
Rival
Doctorant(e), Inserm
  IGF Sud 221
  04 34 35 92 13
Know more >

Chloe
Rossignol
Doctorant(e), UM
  La Colombière E5
  04 99 61 45 68
Know more >

Dorina
Toderasc
Doctorant(e), CNRS
  IGF Sud 224
  04 34 35 92 15
Know more >

Clara
Zirah
Doctorant(e), UM
  IGF Sud 224
  04 34 35 92 15
Know more >

Charleine
Zussy
Chercheur CDD, UM
  IGF Sud 219
  04 34 35 92 23
Know more >

Fixed term contract technicians and engineers
Ophélie
Bento
IE CDD, CNRS
  IGF Sud 224
  04 34 35 92 15
Know more >

Morgane
Denus
IE CDD, CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Camille
Enjolras
IE CDD, CNRS
  IGF Sud 225
  04 34 35 93 19
Know more >

Magalie
Mathias
IE CDD, UM
  IGF Sud 219
  04 34 35 92 23
Know more >

Tristan
Moujellil Legagneur
IE CDD, Inserm
  IGF Sud 118
  04 34 35 92 20
Know more >

  • Oosterlaken M*, Rogliardo A*, Lipina T*, Lafon PA*, Tsitokana ME, Keck M, Cahuzac H, Prieu-Sérandon P, Diem S, Derieux C, Camberlin C, Lafont C, Meyer D, Chames P, Vandermoere F, Marin P, Prézeau L, Servent D, Salahpour A, Ramsey AJ, Bécamel C, Pin JP*, Kniazeff J*, Rondard P*. Nanobody therapy rescues behavioural deficits of NMDA receptor hypofunction. Nature. 2025 Sep;645(8079):262-270. doi: 10.1038/s41586-025-09265-8. PMID: 40702184.
  • Philibert CE, Disdier C, Lafon PA, Bouyssou A, Oosterlaken M, Galant S, Pizzoccaro A, Tuduri P, Ster J, Liu J, Kniazeff J, Pin JP, Rondard P, Marin P*, Vandermoere F*. TrkB receptor interacts with mGlu2 receptor and mediates antipsychotic-like effects of mGlu2 receptor activation in the mouse. Sci Adv. 2024 Jan 26;10(4):eadg1679. doi: 10.1126/sciadv.adg1679. PMID: 38277461.
  • Hinsinger G, Du Trieu de Terdonck L, Urbach S, Salvetat N, Rival M, Galoppin M, Ripoll C, Cezar R, Laurent-Chabalier S, Demattei C, Agherbi H, Castelnovo G, Lehmann S, Rigau V,  Marin P, Thouvenot E. CD138 as specific CSF biomarker of multiple sclerosis Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200230. doi: 10.1212/NXI.0000000000200230, PMID: 38669615
  • Sekssaoui M, Bockaert J, Marin P*, Bécamel C*. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player? Neuropsychopharmacology 2024 Jan 11. doi:10.1038/s41386-024-01794-6. PMID: 38212441.
  • Sengupta S, Mondal M, Prasasvi KR, Mukherjee A, Magod P, Urbach S, Friedmann- Morvinski D*, Marin P*, Somasundaram K*. Differentiated glioma cell-derived fibromodulin activates integrin-dependent Notch signaling in endothelial cells to promote tumor angiogenesis and growth. Elife 2022 Jun 1;11:e78972. doi:10.7554/eLife.78972. PMID: 35642785.
  • Fumagalli A, Heuninck J, Pizzoccaro A, Moutin E, Koenen J, Séveno M, DurrouxT, Junier MP, Schlecht-Louf G, Bachelerie F, Schütz D, Stumm R, Smit MJ, Guérineau NC, Chaumont-Dubel S, Marin P. The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication. Nat Commun. 2020 Sep 25;11(1):4855. doi: 10.1038/s41467-020-18634-y. PMID: 32978390.
  • Berthoux C, Hamieh AM, Rogliardo A, Doucet EL, Coudert C, Ango F, Grychowska K, Chaumont-Dubel S, Zajdel P, Maldonado R, Bockaert J, Marin P*, Bécamel C*. Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Mol Med. 2020 May 8;12(5):e10605. doi:10.15252/emmm.201910605. Epub 2020 Apr 24. PMID: 32329240.
  • Pujol CN, Dupuy V, Séveno M, Runtz L, Bockaert J, Marin P*, Chaumont-Dubel S*. Dynamic interactions of the 5-HT6 receptor with protein partners control dendritic tree morphogenesis. Sci Signal. 2020 Feb 11;13(618):eaax9520. doi: 10.1126/scisignal.aax9520. PMID: 32047117.
  • Rochais C, Lecoutey C, Hamidouche K, Giannoni P, Gaven F, Cem E, Mignani S, Baranger K, Freret T, Bockaert J, Rivera S, Boulouard M, Dallemagne P, Claeysen S. Donecopride, a Swiss army knife with potential against Alzheimer’s disease. Br J Pharmacol. 2020 May;177(9):1988-2005. doi: 10.1111/bph.14964. PMID: 31881553.
  • Murat S, Bigot M, Chapron J, König GM, Kostenis E, Battaglia G, Nicoletti F, Bourinet E, Bockaert J, Marin P*, Vandermoere F*. 5-HT2A receptor- dependent phosphorylation of mGlu2 receptor at Serine 843 promotes mGlu2 receptor-operated Gi/o signaling. Mol Psychiatry. 2019 Nov;24(11):1610-1626. doi: 10.1038/s41380-018-0069-6. PMID: 29858599.

Interactomics and neuropathologies

Principal investigator
Philippe MARIN

Find out more

Microbiota, serotonin and neurodegenerative diseases

Principal investigator
Sylvie CLAEYSEN

Find out more

Serotonin receptors and psychiatric disorders

Principal investigator
Carine BÉCAMEL

Find out more

Mechanisms of Action of Psychedelics as Antidepressants

Responsable
Olivier CAILLARD

En savoir plus

Identification and functional analysis of multiple sclerosis biomarkers

Principal investigator
Eric THOUVENOT

Find out more

HYDRA – Homeostasis and Physiological Dysregulation in Alzheimer’s Disease

Principal investigator
Laurent GIVALOIS

Find out more

Temperature and Circadian control of Alzheimer’s disease pathophysiology

Principal investigator
Geoffrey CANET

Find out more

Protein trafficking and neurodegenerative diseases

Principal investigator
Julien VILLENEUVE

Find out more

Normal and pathological functions of Tau / Eco-emotions and mental health

Principal investigator
Marie-Laure PARMENTIER

Find out more

Neuron-Glia communication during developmental and pathological neurodegeneration

Principal investigator
Ana BOULANGER

Find out more

GPCR signaling, compartmentalization and pathophysiological roles

Principal investigator
Séverine CHAUMONT-DUBEL

Find out more

PhD students


Lucie PELLISSIER

2004 – 2009

CRCN CNRS, Tours, France – ERC Starting Grant 2019 –CNRS Bronze Medal 2022


Gaëlle CARRAT

2007 – 2010

Clinical Research Associate, Medpace, Londres, Angleterre, Royaume-Uni


Julie MEFFRE

2007 – 2011

Assistant Professor, Marseille, France


Samah KARAKI

2008 – 2011

Founder of the Social Brain Institute, Paris, France


Maud COCHET

2007 – 2011

Pedagogical coordinator Lyon, France


Alexander BARRE

2009 – 2013

Patch Clamp engineer, Neuroservices, Aix en Provence, France


Romain DONNEGER

2010 – 2014

Lead Clinical Operations, Roche, Paris, France


Fanny DUHR

2011 – 2015

MD, France


Geoffrey HINSINGER

2013 – 2016

Psychiatric intern, AP-HM, Marseille, France


Coralie BERTHOUX

2013 – 2017

Staff scientist, Albert Einstein College of Medicine, NY, USA


Camille PUJOL

2014 – 2018

Psychiatric intern, CHRU Strasbourg, France – Madeleine Lecoq Award from Académie des Sciences 2022


Samy MURAT

2014 – 2018

Intern in Geriatrics, CHU Nîmes, France


Amos FUMAGALLI

2015 – 2019

Postdoc The Netherlands Cancer Institute, Amsterdam, Netherlands – Recipient of 2 bourses Marie Curie


Bérénice HATAT

2016 – 2019

Odontology student, Montpellier, France


Hugo PAYAN

2016 – 2020

Postdoc, Duke-NUS Medical School, Singapour


Angelina ROGLIARDO

2017 – 2021

Postdoc, INM, Montpellier, France


Vincent DUPUY

2017 – 2021

Postdoc, IINS, Bordeaux, France


Caroline ISMEURT

2017 – 2021

Postdoc, IGMM, Montpellier, France


Lucile DU TRIEU DE TERDONCK

2017 – 2021

Postdoc, INP, Marseille, France


Clémentine PHILIBERT

2018 – 2022

Postdoc, Boston University School of Medicine, Boston, USA


Ophélie BENTO

2020 – 2023

Postdoc, IGF, Montpellier, France


Manon GALOPPIN

2020 – 2023

Postdoc, PhyMedExp, Montpellier, France


Alessandro RABBITO

2020 – 2024

Postdoc, USA


Aurore FILAQUIER

2021 – 2024

Pharmacienne, Péron, France


Candice DISDIER

2021 – 2024

–


Mehdi SEKSSAOUI

2021 – 2025

–


Thomas CUREL

2021 – 2025

–

Post-doctoral fellows


Elena MARCELLO

2011 – 2012

Associate Professor, Univ. Milano, Italy


Paul DELERIS

2012 – 2014

Associate Professor, Univ. Nantes, France


Pascal SEYER

2012 – 2015

Associate Professor Univ. Montpellier, France


Patrizia GIANNONI

2011 – 2016

Associate Professor, Univ. Nîmes, France


Al Mahdy HAMIEH

2015 – 2016

Clinical and preclinical studies manager, Virbac, PACA, France


Simon NICOT

2017 – 2018

Post-doc EFS, Montpellier, France


Émilie DOUCET

2016 – 2020

Laboratory Manager Nervosave Therapeutics, Montpellier, France


Tomas DEL OLMO

2020 – 2025

Postdoc, IGH, Montpellier, France


Lucy KUNDURA

2023 – 2024

R&D project manager, Ciloa, Montpellier, France

Clinical studies conducted by the team

MICMALZ – Analysis of the microbiota’s blood signature as a diagnostic marker for Alzheimer’s disease in its early stages: Pilot study
S. Claeysen (IGF) / A. Gabelle & K. Bennys (CMRR, CHU Montpellier)

The aim of this study is to characterize the composition of the microbiota, in stool and blood, of patients with Alzheimer’s disease (AD, Alzheimer’s group) and people with memory complaints unrelated to AD (Control group). Participants without memory defects are also included in the study (Neurotypical group).
To date, we have included 116 subjects and are continuing recruitment for the Neurotypical group.

Contact

D-Lay MS – Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
E. Thouvenot (IGF, CHU Nîmes)

This is the largest randomized, double-blind clinical trial to assess the clinical efficacy of high-dose vitamin D versus placebo in reducing multiple sclerosis (MS) activity after a first clinical attack of the disease.
In 35 centers in France, we included 316 patients followed for two years and studied the impact of vitamin D on the clinical and MRI evolution of MS.

Contact

VDSS – Peripheral Immunological Effects of High-dose Vitamin D Treatment in Healthy Subjects
E. Thouvenot (IGF, CHU Nîmes)

The aim of this study was to clarify the immunomodulatory effects of Vitamin D (3 months treatment with cholecalciferol 100,000 IU) on lymphocytes from healthy subjects, to establish a normal regulatory profile and thus define potential pathological regulations in MS patients included in D-Lay MS. To this end, we randomized 56 healthy subjects to vitamin D or placebo for 3 months and collected blood samples (PBMC) at inclusion and at 3 months.
We also took stool samples at 3 months to characterize the composition of the microbiota, in stool and blood, of healthy subjects, to study the effects of vitamin D and to serve as a reference for other studies by the team.

Contact